DUBLIN, April 24, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021" report to their offering.
The global hypertrophic cardiomyopathy therapeutics market to grow at a CAGR of 1.80% during the period 2017-2021.
The report, Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
According to the report, one driver in market is increasing cases of HF. HCM is an extended form of a diastolic HF when the heart fails to perform its functions normally. The diastolic HF occurs when the lower left chamber or the LV is not filled properly with blood during the diastolic phase. Therefore, the amount of pumped blood is less than the normal. Similarly, in HCM, the increasing myocardium size results in smaller LV cavity size accompanied by impairment of blood flow. This leads to the common symptoms of both HCM and HF such as dyspnoea, angina, palpitations, syncope, and presyncope. Hence, the drug development for relieving the symptoms of HF benefits the global HCM therapeutics market as well.
As per the CDC, more than five million people are living with HF in the US, and about half of the affected population succumb within five years of diagnosis. However, the deaths due to HF have significantly declined in the past few years due to improved therapies to treat the disease. However, the risk of developing HF continues to rise with the increasing population. This risk-factor has further triggered R&D for newer drugs, which can be re-purposed for the diagnosis and treatment of HCM. The traditional HCM drug market has a long history of re-purposed drugs for its prevention and cure. There are many drugs belonging to drug classes such as beta-adrenergic blockers, calcium channel blockers, and anti-arrhythmic, which were originally developed for the treatment and prevention of HF and are now being employed in the treatment of HCM.
Other Prominent Vendors
- Gilead Sciences
- Teva Pharmaceutical Industries
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Key clinical trials
PART 07: Market dynamics
PART 08: Market landscape
PART 09: Market segmentation by drug-class
PART 10: Geographical segmentation
PART 11: Decision framework
PART 12: Drivers and challenges
PART 13: Market trends
PART 14: Vendor landscape
PART 15: Key vendor analysis
PART 16: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/z2kjx6/global
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-hypertrophic-cardiomyopathy-therapeutics-market-to-grow-18-by-2021---more-than-5-million-people-are-living-with-hf-in-the-united-states---research-and-markets-300444046.html
SOURCE Research and Markets